AstraZeneca Pharmaceuticals: Management of Factor Xa Inhibitor-Related Life-Threatening or Uncontrolled Bleeding
Sunday, October 2
2:30 p.m.–3:15 p.m.
Location: Expert Theater 1
Ilya Danelich, PharmD, BCPS, BCCP, US Medical Director – Coagulation, BioPharmaceuticals Medical Unit
This program will discuss the burden of life-threatening bleeds related to FXa inhibitors, and focus on the mechanism of action, efficacy, and safety of a reversal agent indicated for patients treated with anticoagulants who have life-threatening bleeding.